EyePoint (EYPT) Net Cash Flow Growth (3y) (2013 - 2026)

EyePoint (EYPT) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) NCF Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -50.33%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 38.47%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 33.37%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -29.82%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 EyePoint 358.61 Mn 136.07 Mn 168,000.00 -63.61%

Historic Data

Download Data
DateValue
Mar 31, 2026 -63.61%
Dec 31, 2025 10.36%
Sep 30, 2025 35.85%
Jun 30, 2025 10.29%
Mar 31, 2025 42.63%
Dec 31, 2024 -30.38%
Sep 30, 2024 -11.37%
Jun 30, 2024 -154.39%
Mar 31, 2024 -28.25%
Dec 31, 2023 109.23%
Sep 30, 2023 -45.97%
Jun 30, 2023 127.07%
Mar 31, 2023 35.36%
Dec 31, 2022 60.35%
Sep 30, 2022 18.26%
Jun 30, 2022 -199.34%
Mar 31, 2022 -244.65%
Dec 31, 2021 108.61%
Sep 30, 2021 -29.76%
Jun 30, 2021 -34.31%